drugset / Trial / NCT01193517
Azacitidine and CAPOX in Metastatic Colorectal Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The goal of the Phase I portion of this study is to find the highest tolerable dose of azacitidine combined with capecitabine and oxaliplatin (CAPOX) that can be given to patients with metastatic colorectal cancer. The goal of the Phase II portion of this study is to learn if azacitidine, given in combination with CAPOX, can help to control metastatic colorectal cancer. The safety of this drug combination will also be studied.
Timeline
- Start
- 2010-08
- Primary completion
- 2016-11
- Completion
- 2016-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 75 mg/m2 | Subcutaneous |
| Subject | Capecitabine | Small molecule | 1500 mg/m2 | Oral |
| Subject | Oxaliplatin | Small molecule | 90 mg/m2 | Intravenous |